泽璟制药宣布,若合作方艾伯维公司行使许可选择权,公司将获得1亿美元的首付款,并有资格获得最高达11亿美元的里程碑付款。此次合作涉及特定创新药物的授权许可,彰显了泽璟制药研发实力的国际认可。协议具体条款将根据研发进展分阶段触发付款条件,为泽璟制药带来长期现金流支持。
泽璟制药宣布,若合作方艾伯维公司行使许可选择权,公司将获得1亿美元的首付款,并有资格获得最高达11亿美元的里程碑付款。此次合作涉及特定创新药物的授权许可,彰显了泽璟制药研发实力的国际认可。协议具体条款将根据研发进展分阶段触发付款条件,为泽璟制药带来长期现金流支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.